Phase 2 Study of Chronic Hepatitis C Treatment By Merck Shows Promise
Hepatitis C, News
Data from the C-WORTHY study evaluating the efficacy of treatment with Grazoprevir/Elbasvir of Chronic Hepatitis C in genotype 1 infected treatment-naïve and non-responders to peg-interferon/ribavirin (RP) patients was announced by ... Read more